+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Vaccine Contract Manufacturing Market Research Report by Function, by Applications - Global Forecast to 2025 - Cumulative Impact of COVID-19

  • ID: 4857952
  • Report
  • June 2020
  • Region: Global
  • 236 pages
  • 360iResearch™
UP TO OFF
until Dec 31st 2020

Enquire about COVID-19 updates for this product.

Enquire Now
The Global Vaccine Contract Manufacturing Market to Grow USD 3,711.34 Million by 2025, at a CAGR of 11.88%

FEATURED COMPANIES

  • Ajinomoto Althea, Inc.
  • Cobra Bio
  • GlaxoSmithKline PLC
  • IDT Biologika
  • LONZA
  • Paragon Bioservices, Inc.
  • MORE
The Global Vaccine Contract Manufacturing Market is expected to grow from USD 1,891.79 Million in 2019 to USD 3,711.34 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 11.88%.

Market Segmentation & Coverage:

This research report categorizes the Vaccine Contract Manufacturing to forecast the revenues and analyze the trends in each of the following sub-markets:

On the basis of Function, the Vaccine Contract Manufacturing Market is examined across Downstream and Upstream. The Downstream further studied across Analytical & QC studies, Fill & Finish Operations, and Packaging. The Upstream further studied across Bacterial Expression Systems, Baculovirus/Insect Expression Systems, Mammalian Expression Systems, and Yeast Expression Systems.

On the basis of Type, the Vaccine Contract Manufacturing Market is examined across Attenuated Vaccine, DNA Vaccines, Inactivated Vaccine, Subunit Vaccines, and Toxoid Vaccines.

On the basis of Applications, the Vaccine Contract Manufacturing Market is examined across Human Use and Veterinary.

On the basis of Geography, the Vaccine Contract Manufacturing Market is examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region is examined across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region is examined across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region is examined across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Vaccine Contract Manufacturing Market including Ajinomoto Althea, Inc., Albany Molecular Research, Inc., Catalent, Inc., Cobra Bio, Cytovance Biologics, FUJIFILM Diosynth Biotechnologies, GlaxoSmithKline PLC, ICON PLC, IDT Biologika, KBI Biopharma, LONZA, Merck KGaA, Paragon Bioservices, Inc., Pfizer, Inc., Pharmaceutical Product Development, LLC, and PRA Health Sciences.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Vaccine Contract Manufacturing Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Vaccine Contract Manufacturing Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Vaccine Contract Manufacturing Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Vaccine Contract Manufacturing Market?
4. What is the competitive strategic window for opportunities in the Global Vaccine Contract Manufacturing Market?
5. What are the technology trends and regulatory frameworks in the Global Vaccine Contract Manufacturing Market?
6. What are the modes and strategic moves considered suitable for entering the Global Vaccine Contract Manufacturing Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Ajinomoto Althea, Inc.
  • Cobra Bio
  • GlaxoSmithKline PLC
  • IDT Biologika
  • LONZA
  • Paragon Bioservices, Inc.
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
2.3.1. Competitive Strategic Window

3. Executive Summary
3.1. Market Outlook
3.2. Function Outlook
3.3. Type Outlook
3.4. Applications Outlook
3.5. Geography Outlook
3.6. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Vaccine Contract Manufacturing Market, By Geography

5. Market Dynamics
5.1. Introduction
5.1.1. Drivers
5.1.1.1. Increasing demand for vaccines leading to capacity expansion by contract manufacturers
5.1.1.2. Paradigm shift toward cell-based vaccine production
5.1.1.3. Key advantages such as cost and time saving offered by contract services
5.1.1.4. Vaccination coverage across the globe
5.1.2. Restraints
5.1.2.1. Limited outsourcing by well-established vaccine manufacturers
5.1.3. Opportunities
5.1.3.1. Rising global demand to cater to the growing population of varied age groups
5.1.3.2. Innovation and robust vaccine pipeline
5.1.3.3. Favorable government insights and guidelines to speed up the vaccine manufacturing
5.1.4. Challenges
5.1.4.1. Pharma companies manufacturing operations in-house to gain strategic control

6. Market Insights
6.1. Porters Five Forces Analysis
6.1.1. Threat of New Entrants
6.1.2. Threat of Substitutes
6.1.3. Bargaining Power of Customers
6.1.4. Bargaining Power of Suppliers
6.1.5. Industry Rivalry
6.2. Cumulative Impact of COVID-19
6.3. Client Customizations
6.3.1. Supply Chain Trend Associated with COVID-19
6.3.2. Automation in Vaccine Development
6.3.3. Collaborative Landscape among Bioprocessing Companies

7. Global Vaccine Contract Manufacturing Market, By Function
7.1. Introduction
7.2. Downstream
7.2.1. Analytical & QC studies
7.2.2. Fill & Finish Operations
7.2.3. Packaging
7.3. Upstream
7.3.1. Bacterial Expression Systems
7.3.2. Baculovirus/Insect Expression Systems
7.3.3. Mammalian Expression Systems
7.3.4. Yeast Expression Systems

8. Global Vaccine Contract Manufacturing Market, By Type
8.1. Introduction
8.2. Attenuated Vaccine
8.3. DNA Vaccines
8.4. Inactivated Vaccine
8.5. Subunit Vaccines
8.6. Toxoid Vaccines

9. Global Vaccine Contract Manufacturing Market, By Applications
9.1. Introduction
9.2. Human Use
9.3. Veterinary

10. Americas Vaccine Contract Manufacturing Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Vaccine Contract Manufacturing Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. South Korea
11.10. Thailand

12. Europe, Middle East & Africa Vaccine Contract Manufacturing Market
12.1. Introduction
12.2. France
12.3. Germany
12.4. Italy
12.5. Netherlands
12.6. Qatar
12.7. Russia
12.8. Saudi Arabia
12.9. South Africa
12.10. Spain
12.11. United Arab Emirates
12.12. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding

14. Company Usability Profiles
14.1. Ajinomoto Althea, Inc.
14.2. Albany Molecular Research, Inc.
14.3. Catalent, Inc.
14.4. Cobra Bio
14.5. Cytovance Biologics
14.6. FUJIFILM Diosynth Biotechnologies
14.7. GlaxoSmithKline PLC
14.8. ICON PLC
14.9. IDT Biologika
14.10. KBI Biopharma
14.11. LONZA
14.12. Merck KGaA
14.13. Paragon Bioservices, Inc.
14.14. Pfizer, Inc.
14.15. Pharmaceutical Product Development, LLC
14.16. PRA Health Sciences

15. Appendix
15.1. Discussion Guide
15.2. Edition Details
15.3. License Details
15.4. Pricing Details
Note: Product cover images may vary from those shown
  • Ajinomoto Althea, Inc.
  • Albany Molecular Research, Inc.
  • Catalent, Inc.
  • Cobra Bio
  • Cytovance Biologics
  • FUJIFILM Diosynth Biotechnologies
  • GlaxoSmithKline PLC
  • ICON PLC
  • IDT Biologika
  • KBI Biopharma
  • LONZA
  • Merck KGaA
  • Paragon Bioservices, Inc.
  • Pfizer, Inc.
  • Pharmaceutical Product Development, LLC
  • PRA Health Sciences
Note: Product cover images may vary from those shown
Adroll
adroll